BioSpace News Archive

Anavex Life Sciences Corp. today announced that it will issue financial results for its fiscal year ended September 30, 2023, on Monday November 27, 2023.

DxVx announces today that it will conduct its own clinical trials of OVM-200, an anti-cancer vaccine from Oxford Vacmedix(OVM) by license-in agreement and develop further with its own new drug development knowledge.

NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company” or “NurExone”), a pioneering biotechnology company, released a corporate update and reported financial results for the quarter ended September 30, 2023.

Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”) today announced the Company has received notice from The Nasdaq Capital Market, LLC (“Nasdaq”), dated November 22, 2023, informing Novo that it has regained compliance with the minimum bid price requirement as set forth under NASDAQ Listing Rule 5550(a)(2) for continued listing on Nasdaq.

Ascentage Pharma hosted a ceremony in Suzhou, China, marking the launch of olverembatinib in a newly approved indication and the dispatch of the first batch of the drug for the new indication.

Compass Pathways plc announced today that management will hold a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference at 10:25 am ET on November 30, 2023.

Protect Pharmaceutical Corp. “OTC: PRTT” is pleased to announce the acquisition of Bosfor Export.

Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today reported new preclinical data providing further support for its lead assets, the IL1RAP-binding antibodies nadunolimab (CAN04) and CAN10, in both cancer and cardiovascular disease.